Featured News
Charles River Acquires Retrogenix®
The acquisition of Retrogenix® enhances Charles River’s scientific expertise with additional large molecule and cell therapy capabilities. The proprietary Retrogenix® Cell Microarray Technology uncovers high quality, exploitable drug targets and mechanisms of action as well as screens for potential off-targets to inform lead selection and generates high quality IND-enabling specificity data.
Retrogenix® Cell Microarray Technology can be applied to receptor identification, off-target screening, and target deconvolution on a wide range of novel therapeutics including biologics, cell therapies, and small molecules, and provides the premier platform for off-target screening for preclinical safety assurance in CAR-T therapies. Combined with Distributed Bio’s large-molecule discovery platform, the acquisition of Retrogenix® will further strengthen Charles River’s integrated, end-to-end solution for therapeutic antibody and cell and gene therapy discovery and development.